The main cause of mortality among patients with breast cancer is the metastatic spread of the primary tumour. The urinary bladder is considered as an unusual site for breast cancer metastasis. A patient has presented with right breast tumour and qualified for surgical treatment. After removal of the mass, an intra-operative and final pathology evaluation indicated breast invasive lobular carcinoma. Adjuvant chemotherapy was given. Years later, an increase of serum CA15-3 tumour marker level was noted and physical examination revealed a lump at the mastectomy scar. A follow-up abdominal ultrasound scan demonstrated thickening of the urinary bladder wall segment, confirmed later by CT scan. A transurethral resection of bladder was performed, reaffirming a neoplastic mass, with histological assessment revealing invasive breast carcinoma. Palliative chemotherapy was given and another follow-up ultrasound scans were unremarkable. The patient is alive today.
CASE REPORT
A 47year old woman has presented with a palpable right breast tumour. Mammography demonstrated an architectural distortion with speculations measuring 30mm located deep in the chest wall. Mammography of the left breast was unremarkable. No enlarged axillary lymph nodes were present (Fig. 1 ). Due to dense breast tissue texture and the palpable right breast lump, an ultrasound scan was performed, showing a hypoechogenic, retro-areolar heterogeneous mass, measuring up to 30mm. A guided fine needle aspiration biopsy revealed material suspected of malignancy. After the removal of the mass, an intra-operative pathology evaluation indicated breast invasive lobular carcinoma. Subsequently, right-sided radical mastectomy and lymphadenectomy were performed. The final morphological assessment of the surgical specimen confirmed the presence of bifocal invasive lobular carcinoma. The patient underwent adjuvant chemotherapy with CMF regimen (Cyclophosphamide, Methotrexat, Fluorouracil ).
Six years later, an increase of blood serum CA 15-3 tumour marker level was noted (from 21.98 U/ml to 43.2 U/ml) during a routine follow-up. The physical examination revealed a 1cm lesion within the post-mastectomy scar which after excision was diagnosed microscopically as disease recurrence. Despite removal of the recurrent mass, the serum CA 15-3 concentration constantly increased up to 179.7 U/ml. A follow-up abdominal ultrasound scan, performed one month later, demonstrated thickening up to 9mm of a 6cm long leftposterior urinary bladder wall segment ( Fig. 2; Fig. 3 ).
This abnormality was later confirmed by computed tomography scan presenting an irregular bladder wall thickening on 2/3 of its circumference, involving both ureteral outlets. No hydronephrosis was observed at this stage and the patient remained completely asymptomatic ( Fig. 4; Fig. 5 ; Fig.  6 ; Fig. 7; Fig. 8 ). As a next step a transurethral resection of bladder (TURB) was performed, reaffirming a neoplastic mass mainly around the left ureteral site, with all lesions being resected to the muscular layer. Histological assessment of the specimen revealed a disperse cancer infiltration of the bladder mucosa.
The neoplasm consisted of cells which cytologically and immunohistochemically corresponded with the features of the primary lobular breast carcinoma (Fig. 9) . The patient was qualified for palliative chemotherapy with AT regimen (Adriamycin, Taxotere).
Another follow-up abdominal ultrasound scan did not present any pathological changes and metastatic workups were negative. The patient is alive today with no signs of recurrent disease.
Breast cancer is by far the most common cancer affecting women, with more than one million being diagnosed every year and more than 410,000 dying from the disease worldwide [1, 2] . The main cause of mortality among these patients is attributed to metastatic spread of the primary tumour. The urinary bladder is considered as an unusual site of breast cancer metastasis, and such a spread has been reported in the literature very rarely.
The first examples of such atypical neoplastic involvement were discovered through autopsy reports [3, 4] . A review of the English literature up to 2008 revealed only 34 cases of living patients with primary breast cancer metastatic to the bladder [5, 6] . Breast cancer commonly spreads to the lymph-nodes, lungs, bones, liver and skin, less frequently involving the brain, adrenal glands, ovaries, spleen, pancreas, kidneys, thyroid and heart. On the other hand, the most common primary tumours that metastasize to the urinary bladder are stomach, lung and skin (melanoma) [7, 8] .
In the majority of reported cases, the urinary bladder lesions from breast cancer were part of systemic dissemination. This observation indicates that bladder metastases are typically late complications of primary disease [9] . Nevertheless the presented case is an unusual example of solitary distant organ metastasis. Some authors have linked the likelihood of developing bladder metastasis with prolonged steroid therapy due to the possible influence of immuno-suppressive effects on carcinoma spreading routes [10] .
The metastatic pattern of breast carcinoma may be related to the histologic type of cancer [7] . It has been suggested that infiltrating lobular carcinoma (ILC), which according to multiple sources accounts for 8-14% of all cases of breast primary tumors, has a higher bladder metastatic rate in comparison with infiltrating ductal carcinoma representing 65-85% of breast cancers. It is postulated that breast neoplasm metastasizes to the bladder via retroperitoneal lymphatic involvement, observed more frequently in ILC cases [11, 12, 13] .
In patients with a history of breast cancer, particularly with a lobular subtype, even very subtle lower urinary tract symptoms (LUTS) should be thoroughly evaluated for the possibility of bladder metastasis. Clinical presentation may vary, ranging from the most common painless haematuria, stress and urge incontinence, frequency and nocturia to rare signs like dysuria and back pain [14] . In the described case the patient was completely asymptomatic as far as LUTS are concerned, with first clues of bladder involvement being revealed on abdominal ultrasound scan. Other helpful diagnostic investigations should include cystoscopy and biopsy of any suspicious findings. Feldman et al. stated that assessment should also include further imaging studies, citing a case with a negative cystoscopy picture despite strong evidence of bladder involvement from the patient's symptoms, ultrasound and CT scans [7] . Extending the range of imaging modalities by MRI scan would help in definitive confirmation of neoplastic bladder infiltration. Moreover, it would help in precise local cancer staging and in the exclusion of adjacent structure involvement (ie uterus and adnexa).
The (18F-FDG) Positron Emission Tomography (PET) imaging in localized bladder tumours has been considered of limited value due to urinary excretion of the tracer, making the evaluation of bladder wall lesions difficult [15] . However, efforts are made to overcome this problem with interventions such as catheterization, bladder irrigation and enforced diuresis. High 18F-FDG concentration in the bladder tumour indicate that PET and particularly PET/CT scanning might be feasible, contributing significantly to the imaging evaluation of patients with bladder neoplasm. Other studies have recently reported 11C-choline as a new tracer with lack of urinary excretion [16] .
Patient assessment should also include verification of blood serum CA15-3 level which remains the most sensitive tumour marker in breast cancer follow up. Its main function is to monitor patient response to treatment and watch for cancer recurrence [17] .
Awareness of such a metastatic route of breast cancer is important, since haematuria among patients receiving cyclophosphamide, a common cytotoxic drug used in adjuvant settings, may be easily dismissed as cystitis secondary to chemotherapy, leaving the metastatic bladder spread undiagnosed [18] .
In conclusion, the evaluation of patients with a history of breast cancer developing urinary symptoms should include the potential presence of urinary bladder metastasis. Investigations undertaken in these patients should therefore include imaging studies (ultrasound and CT followed by MRI scan), cystoscopy and also mapping biopsy whenever bladder involvement is suspected.
In patients with a history of breast cancer, particularly with a lobular subtype, a thorough radiological examination (ultrasound, CT, MRI followed by cystoscopy and mapping biopsy) of even the most unlikely secondary sites should be performed. Very subtle lower urinary tract symptoms may be the first signs of possible bladder metastasis. 
